Greater Cannabis Company (GCAN) Return on Capital Employed (2018 - 2026)
Greater Cannabis Company's (GCAN) quarterly Return on Capital Employed came in at 22.29% in Q1 2026, up 549.0% year-on-year from 3.43% in Q1 2025, and down 10.91% quarter-over-quarter from 25.02% in Q4 2025.
Greater Cannabis Company (GCAN) Return on Capital Employed (2018 - 2026) Analysis & Trends
Greater Cannabis Company's Return on Capital Employed history runs 9 years deep, the most recent figure standing at 22.29% for Q1 2026.
- On a quarterly basis, Return on Capital Employed rose 549.0% year-over-year to 22.29% in Q1 2026; TTM through Mar 2026 was 22.29%, a 549.0% increase from a year earlier, with the FY2025 full-year figure at 25.66%, up 570.0% from the prior year.
- Return on Capital Employed retreated to 22.29% in Q1 2026 per GCAN's latest filing, from 25.02% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 48.98% in Q1 2022 and bottomed at 15.09% in Q3 2025.
- The 5-year median for Return on Capital Employed is 25.47% (2024), against an average of 27.67%.
- Across the five-year window, Return on Capital Employed plunged 9665 bps in 2022 and surged 636 bps in 2025, its largest moves.
- Year by year, Return on Capital Employed stood at 33.11% in 2022, then decreased by 18 bps to 27.22% in 2023, then plunged by 31 bps to 18.67% in 2024, then soared by 34 bps to 25.02% in 2025, then declined by 11 bps to 22.29% in 2026.
- Per Business Quant, the three latest GCAN Return on Capital Employed figures stand at 22.29% (Q1 2026), 25.02% (Q4 2025), and 15.09% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 8.52% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 27.36% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -1.50% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 21.43% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 0.46% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 20.04% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 5.24% |
| 10 | Greater Cannabis Company | 292,929.85 | 292,929.85 | - | 22.29% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 22.29% |
| Dec 31, 2025 | 25.02% |
| Sep 30, 2025 | 15.09% |
| Jun 30, 2025 | 15.99% |
| Mar 31, 2025 | 16.81% |
| Dec 31, 2024 | 18.67% |
| Sep 30, 2024 | 20.66% |
| Jun 30, 2024 | 23.80% |
| Mar 31, 2024 | 25.47% |
| Dec 31, 2023 | 27.22% |
| Sep 30, 2023 | 27.59% |
| Jun 30, 2023 | 27.51% |
| Mar 31, 2023 | 30.11% |
| Dec 31, 2022 | 33.11% |
| Sep 30, 2022 | 46.36% |
| Jun 30, 2022 | 45.67% |
| Mar 31, 2022 | 48.98% |
| Dec 31, 2021 | 83.56% |
| Sep 30, 2021 | 117.28% |
| Jun 30, 2021 | 142.32% |